CROI: Tenofovir/emtricitabine/efavirenz less likely to cause adverse birth outcomes than other regimens, Botswana study finds

Carole Leach-Lemens

Infants exposed to an antiretroviral regimen of tenofovir, emtricitabine and efavirenz (Atripla) from conception experienced fewer adverse birth outcomes compared to other three-drug regimens, according to a study of births in Botswana between 2014 and 2016, presented on Tuesday at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

The Tsepamo study, an observational analysis of approximately 45% of all births in Botswana from August 2014 to August 2016, provides important information on the safety of various regimens in common use in sub-Saharan Africa, Asia and Eastern Europe, where the vast majority of HIV-exposed infants are found.

February 22, 2017
Year of publication
2017
Resource types
Conference materials, Journal and research articles
Countries
Tags
HIV-exposed infants, drug safety, Botswana, peripartum prophylaxis, treatment, ART, antiretroviral therapy, ARVs, antiretroviral drugs, HIV prevention, CROI 2017

Similar Resources

In 2013, Uganda updated its prevention of maternal-to-child transmission of HIV program to Option B+, which requires that all HIV-infected pregnant and breastfeeding women be started on lifelong antiretroviral therapy (ART) regardless of CD4 count…

Initiation of antiretroviral therapy (ART) following diagnosis of HIV infection at birth is an emerging area of paediatric HIV care. We present outcomes of HIV-infected infants identified at birth at Rahima Moosa Mother and Child Hospital in Johannesburg, South Africa.

An essential first step in caring for HIV-infected children is accurate and early diagnosis of HIV, early HIV testing, prompt return of results, and rapid initiation of treatment.

This study aimed to evaluate the impact of clinic-based prevention of mother-to-child transmission (PMTCT) community support by trained lay health workers in addition to standard clinical care on PMTCT infant outcomes.

To understand the uptake of HIV services by adolescent women, the authors conducted a retrospective analysis of patient-level data (2011–2013) on services for antenatal care (ANC) and prevention of mother-to-child transmission (PMTCT) in 36 facilities in 5 districts in Zimbabwe.

This paper documents the development of the global and national monitoring and reporting systems for PMTCT and paediatric HIV care and treatment programmes, achievements and remaining challenges.

Many countries are working to reduce or eliminate mother-to-child transmission (MTCT) of HIV. Prevention efforts have been conceptualized as steps in a cascade but cascade completion rates during and after pregnancy are low.

Baylor-Malawi, with USAID funding, has developed a special JAIDS supplement featuring 11 articles which highlight lessons and best practices from the Accelerating Children’s HIV/AIDS Treatment (ACT) Initiative, a public-private partnership that expanded pediatric HIV services in nine sub-Saharan

The Accelerating Children’s HIV/AIDS Treatment (ACT) Initiative was a public-private partnership that expanded pediatric HIV services in nine sub-Saharan African countries from 2014-2016, providing treatment to more than 560,000 children living with HIV.

Across sub-Saharan Africa, prevention of mother-to-child transmission services are encountering increasing numbers of women already established on antiretroviral therapy (ART) when entering antenatal care.